Daiichi Sankyo Expands Cancer Research and Manufacturing Capacity in Germany

Investment:
Daiichi Sankyo is investing approximately $1 billion to enhance its manufacturing facility in Pfaffenhofen, Germany, focusing on antibody-drug conjugates (ADCs) for cancer therapies13.

Expansion:
The project aims to transform the Pfaffenhofen facility into an international innovation center, with new laboratories dedicated to ADCs, targeting cancers such as breast, lung, and stomach cancers13.

Job Creation:
The investment is expected to create at least 350 new jobs by 2030, including positions for top international scientists, process engineers, and biotechnology specialists13.

Sustainability:
The project includes strengthening logistics and quality assurance systems, as well as implementing additional sustainability mechanisms, such as adopting more renewable energy sources13.

Research Collaboration:
Daiichi Sankyo has previously collaborated with German research institutions, such as the Max Planck Innovation and Lead Discovery Center, to advance cancer research and drug discovery efforts2.

Global Presence:
Daiichi Sankyo has established research institutes in Cambridge, Massachusetts, and Munich, Germany, to foster new innovative ideas and technologies in drug discovery5.

Sources:

1. https://www.biospace.com/daiichi-sankyo-drops-1b-to-boost-adc-manufacturing-capacity-at-german-site

2. https://daiichisankyo.us/en/press-releases/-/article/daiichi-sankyo-max-planck-innovation-and-lead-discovery-center-announce-cancer-research-collaboration

3. https://www.pharmamanufacturing.com/facilities/news/33037340/daiichi-sankyo-to-invest-1b-in-german-innovation-hub

5. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202405/20240522_E.pdf